c-Met raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-08-27. Anything still debated is marked as such rather than presented as settled.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
== T cell Response to MiHAs == The MiHAs bound to a MHC presented on a cell surface may be recognized as a self peptide or not recognized by either CD8+ or CD4+ T cells. The lack of recognition of a T cell to this self antigen is the reason why allogeneic stem cell transplantation for an HLA matched gene or a developing fetus's MiHAs during pregnancy may not be recognized by T cells and marked as foreign leading to an immune response. Although B cell receptors can also recognize MHCs, immune responses seem to only be elicited by T cells. The consequences of an immune response are seen in allogeneic hematopoietic stem cell transplantation (HCT) when the peptides encoded by polymorphic genes differ between the recipient and the donor T cells. As a result, the donor T cells can target the recipients cells called graft-versus-host disease (GVHD). Although graft or bone marrow rejection can have detrimental effects, there are immunotherapy benefits when cytotoxic T lymphocytes are specific for a self antigen and can target antigens expressed selectively on leukemic cells in order to destroy these tumor cells referred to as graft-versus- leukemia effect (GVL). The recognition of a mature T cell to this self antigen should not induce an immune response. During thymic selection occurring in the thymus, only a thymocyte TCR that recognizes either class I or class II MHC molecule plus peptide should survive positive selection.
=== Serotonin === In the brain, serotonin is a neurotransmitter and regulates arousal, behavior, sleep, and mood, among other things. During prolonged exercise where central nervous system fatigue is present, serotonin levels in the brain are higher than normal physiological conditions; these higher levels can increase perceptions of effort and peripheral muscle fatigue. The increased synthesis of brain serotonin occurs because of a higher proportion of tryptophan, the serotonin precursor, in the blood and which results in larger amounts of tryptophan crossing the blood–brain barrier. An important factor of serotonin synthesis is the transport mechanism of tryptophan across the blood–brain barrier. The transport mechanism for tryptophan is shared with the branched chain amino acids (BCAAs), leucine, isoleucine, and valine. During extended exercise, BCAAs are consumed for skeletal muscle contraction, allowing for greater transport of tryptophan across the blood–brain barrier. None of the components of the serotonin synthesis reaction are saturated under normal physiological conditions, allowing for the increased production of the neurotransmitter. However the failure of BCAAs to decrease time to fatigue consistently limit this hypothesis. This may be due to a counter-acting mechanism: BCAAs also limit the uptake of tyrosine, another aromatic amino acid, like tryptophan. Tyrosine is a precursor to catecholamine, which enhances performance drive.
== Taxonomy == The genus Clematis was first published by Carl Linnaeus in Species Plantarum in 1753, the first species listed being Clematis viticella. The genus name long pre-dates Linnaeus. It was used in Classical Greek for various climbing plants, and is based on κλήμα (klēma), meaning vine or tendril.
Another less insidious tactic journals employ is to publish a large portion of its papers, or at least the papers expected to be highly cited, early in the calendar year. This gives those papers more time to gather citations. Several methods, not necessarily with nefarious intent, exist for a journal to cite articles in the same journal which will increase the journal's impact factor. Beyond editorial policies that may skew the impact factor, journals can take overt steps to game the system. For example, in 2007, the specialist journal Folia Phoniatrica et Logopaedica, with an impact factor of 0.66, published an editorial that cited all its articles from 2005 to 2006 in a protest against the "absurd scientific situation in some countries" related to use of the impact factor. The large number of citations meant that the impact factor for that journal increased to 1.44. As a result of the increase, the journal was not included in the 2008 and 2009 Journal Citation Reports. Coercive citation is a practice in which an editor forces an author to add extraneous citations to an article before the journal will agree to publish it, in order to inflate the journal's impact factor. A survey published in 2012 indicates that coercive citation has been experienced by one in five researchers working in economics, sociology, psychology, and multiple business disciplines, and it is more common in business and in journals with a lower impact factor. Editors of leading business journals banded together to disavow the practice.
== Bodybuilding titles == 1984 Mr Birmingham Novice, 1st 1985 World Games, 7th Heavyweights 1986 British Championships, 1st Heavyweight 1988 British Championships, 1st Heavyweight and overall 1990 Night of Champions, 2nd 1991 Night of Champions, 1st 1991 Mr. Olympia, 2nd 1991 English Grand Prix, 1st 1992 Mr. Olympia, 1st 1992 English Grand Prix, 1st 1993 Mr. Olympia, 1st 1994 Mr. Olympia, 1st 1994 Mr. Worldwide, 1st 1994 Spanish Grand Prix, 1st 1994 German Grand Prix, 1st 1994 English Grand Prix, 1st 1995 Mr. Olympia, 1st 1996 Mr. Olympia, 1st 1996 Spanish Grand Prix, 1st 1996 German Grand Prix, 1st 1996 English Grand Prix, 1st 1997 Mr. Olympia, 1st
Sources: en.wikipedia.org
By the time Ferdinand Marcos' second term began, sugar had become a critical Philippine export, responsible for 27% of the county's total foreign exchange earnings. With international sugar prices rising rapidly through the early 1970s, Marcos decided to put domestic and international sugar trading under government control, first through the Philippine Exchange Co. (Philex), and later through the Philippine Sugar Commission (Philsucom) and its trading arm, the National Sugar Trading Corporation (NASUTRA), which were both controlled by Marcos crony Roberto Benedicto. However, the international price of sugar eventually crashed, dramatically hurting the livelihoods of poor farmers. The NASUTRA monopoly forced many sugar planters into bankruptcy or deep in debt. In 1984, over 190,000 sugar workers lost their livelihood, and about a million sacadas and their families in Negros suffered in what would later become known as the "Negros Famine."
=== Molecular absorption === Theoretically graphene makes an excellent sensor due to its 2D structure. The fact that its entire volume is exposed to its surrounding environment makes it very efficient to detect adsorbed molecules. However, similar to carbon nanotubes, graphene has no dangling bonds on its surface. Gaseous molecules cannot be readily adsorbed onto graphene surfaces, so intrinsically graphene is insensitive. The sensitivity of graphene chemical gas sensors can be dramatically enhanced by functionalization, for example, coating the film with a thin layer of certain polymers. The thin polymer layer acts like a concentrator that absorbs gaseous molecules. The molecule absorption introduces a local change in electrical resistance of graphene sensors. While this effect occurs in other materials, graphene is superior due to its high electrical conductivity (even when few carriers are present) and low noise, which makes this change in resistance detectable.
What I mean by reified consciousness, I can illustrate—without elaborate philosophical contemplation—most simply with an American experience. Among the frequently changing colleagues which the Princeton Project provided me with, was a young lady. After a few days, she had gained confidence in me, and asked most kindly: "Dr Adorno, would you mind a personal question?". I said, "It depends on the question, but just go ahead", and she went on: "Please tell me: are you an extrovert or an introvert?" It was as if she, as a living being, already thought according to the model of multi-choice questions in questionnaires.
Primary antioxidants scavenge free radicals formed during the initial (thermal) oxidation process (ROO•), thus preventing chain reactions that lead to polymer degradation. Examples: butylated hydroxytoluene, 2,4-dimethyl-6-tert-butylphenol, para tertiary butyl phenol, 2,6-di-tert-butylphenol, 1,3,5-Tris(4-(tert-butyl)-3-hydroxy-2,6-dimethylbenzyl)-1,3,5-triazinane-2,4,6-trione
==== MeSH E05.318.308 – data collection ==== MeSH E05.318.308.225 – geriatric assessment MeSH E05.318.308.250 – health surveys MeSH E05.318.308.250.149 – behavioral risk factor surveillance system MeSH E05.318.308.250.300 – dental health surveys MeSH E05.318.308.250.300.300 – dental plaque index MeSH E05.318.308.250.300.350 – dmf index MeSH E05.318.308.250.300.675 – oral hygiene index MeSH E05.318.308.250.300.725 – periodontal index MeSH E05.318.308.250.475 – health status indicators MeSH E05.318.308.250.475.365 – apache MeSH E05.318.308.250.475.547 – severity of illness index MeSH E05.318.308.250.475.547.500 – karnofsky performance status MeSH E05.318.308.250.475.730 – sickness impact profile MeSH E05.318.308.250.580 – mass screening MeSH E05.318.308.250.580.174 – anonymous testing MeSH E05.318.308.250.580.350 – genetic screening MeSH E05.318.308.250.580.510 – mass chest x-ray MeSH E05.318.308.250.580.560 – multiphasic screening MeSH E05.318.308.250.580.580 – neonatal screening MeSH E05.318.308.250.580.925 – vision screening MeSH E05.318.308.250.600 – nutrition surveys MeSH E05.318.308.250.600.350 – diet surveys MeSH E05.318.308.250.700 – population surveillance MeSH E05.318.308.250.700.650 – sentinel surveillance MeSH E05.318.308.335 – health care surveys MeSH E05.318.308.420 – interviews MeSH E05.318.308.420.200 – focus groups MeSH E05.318.308.502 – narration MeSH E05.318.308.585 – nutrition assessment MeSH E05.318.308.585.550 – nutrition surveys MeSH E05.318.308.585.550.350 – diet surveys MeSH E05.318.308.750 – questionnaires MeSH E05.318.308.940 – records MeSH E05.318.308.940.250 – birth certificates MeSH E05.318.308.940.350 – death certificates MeSH E05.318.308.940.375 – dental records MeSH E05.318.308.940.425 – hospital records MeSH E05.318.308.940.968 – medical records MeSH E05.318.308.940.968.500 – medical record linkage MeSH E05.318.308.940.968.625 – medical records systems, computerized MeSH E05.318.308.940.968.750 – medical records, problem-oriented MeSH E05.318.308.940.968.875 – trauma severity indices MeSH E05.318.308.940.968.875.125 – abbreviated injury scale MeSH E05.318.308.940.968.875.250 – glasgow coma scale MeSH E05.318.308.940.968.875.260 – glasgow outcome scale MeSH E05.318.308.940.968.875.500 – injury severity score MeSH E05.318.308.940.984 – nursing records MeSH E05.318.308.970 – registries MeSH E05.318.308.970.725 – seer program MeSH E05.318.308.985 – vital statistics MeSH E05.318.308.985.450 – life expectancy MeSH E05.318.308.985.475 – life tables MeSH E05.318.308.985.525 – morbidity MeSH E05.318.308.985.525.080 – basic reproduction number MeSH E05.318.308.985.525.375 – incidence MeSH E05.318.308.985.525.750 – prevalence MeSH E05.318.308.985.550 – mortality MeSH E05.318.308.985.550.250 – cause of death MeSH E05.318.308.985.550.287 – child mortality MeSH E05.318.308.985.550.325 – fatal outcome MeSH E05.318.308.985.550.362 – fetal mortality MeSH E05.318.308.985.550.400 – hospital mortality MeSH E05.318.308.985.550.475 – infant mortality MeSH E05.318.308.985.550.500 – maternal mortality MeSH E05.318.308.985.550.900 – survival rate MeSH E05.318.308.985.775 – pregnancy rate MeSH E05.318.308.985.775.500 – birth rate
Sources: en.wikipedia.org
== Operation == Penning traps use a strong homogeneous axial magnetic field to confine particles radially and a quadrupole electric field to confine the particles axially. The static electric potential can be generated using a set of three electrodes: a ring and two endcaps. In an ideal Penning trap the ring and endcaps are hyperboloids of revolution. For trapping of positive (negative) ions, the endcap electrodes are kept at a positive (negative) potential relative to the ring. This potential produces a saddle point in the centre of the trap, which traps ions along the axial direction. The electric field causes ions to oscillate (harmonically in the case of an ideal Penning trap) along the trap axis. The magnetic field in combination with the electric field causes charged particles to move in the radial plane with a motion which traces out an epitrochoid. The orbital motion of ions in the radial plane is composed of two modes at frequencies which are called the magnetron
=== Dementia === While antipsychotic medications such as risperidone have a slight benefit in people with dementia, they have been linked to a higher incidence of death and stroke. Because of this increased risk of death, treatment of dementia-related psychosis with risperidone is not FDA-approved and carries a black box warning. However, many other jurisdictions regularly use it to control severe aggression and psychosis in those with dementia when other non-pharmacological interventions have failed and their pharmaceutical regulators have approved its use in this population.
=== May === 1 May – Former US President Donald Trump arrives in Aberdeen to visit his Scottish golf properties. 2 May – The Scottish Government reverses plans to give £46m to colleges and universities, having identified the money as an "essential saving". 3 May – The SNP signs a contract with a new auditor, Manchester-based AMS Accountants Group. 4 May – Deputy First Minister Shona Robison confirms the Scottish Government will go ahead with its pledge to provide free school meals for all primary school pupils in Scotland. 5 May – Junior doctors in Scotland vote to stage a three-day strike over their demand for a 23.5% above inflation pay increase from the Scottish Government. 10 May – UK Prime Minister Rishi Sunak urges the Scottish Government to re-think its plans to introduce Highly Protected Marine Areas in Scottish waters, which would restrict fishing and other human activities to preserve the environment. 12 May – The Stand Comedy Club reinstates an Edinburgh Fringe show to be staged by SNP MP Joanna Cherry after previously cancelling it after it said staff were uncomfortable with her views about transgender people. 15 May – Stagecoach Group launches a driverless bus service on the Forth Road Bridge, believed to be the world's first. 16 May – COVID-19 in Scotland: The rules requiring people to wear face masks in Scottish care homes and healthcare settings come to an end after three years. 17 May First Minister Humza Yousaf attends his first audience with King Charles III at Buckingham Palace.
== Properties == Silica gel's high specific surface area—around 750–800 m2/g (230,000–240,000 sq ft/oz)—allows it to absorb water readily, making it useful as a desiccant (drying agent). Silica gel is often described as "absorbing" moisture, which may be appropriate when the gel's microscopic structure is ignored, as in silica gel packs or other products. However, material silica gel removes moisture by adsorption onto the surface of its numerous pores rather than by absorption into the bulk of the gel. Silica gel is able to absorb up to 37% of its own weight in moisture in high-humidity environments. This moisture can be released upon heating at about 120 °C (248 °F) for 1–2 hours. This makes it reusable multiple times with very little, if any, loss of efficiency.
Radioiodine Therapy (RIT) is a nuclear medicine procedure used to treat thyroid hyperfunction, Graves' disease, thyroid enlargement, and certain forms of thyroid cancer. The radioactive iodine isotope used is 131Iodine, a predominant beta emitter with a half-life of eight days, which is only stored in thyroid cells in the human body. In 1942, Saul Hertz (1905-1950) of the Massachusetts General Hospital and the physicist Arthur Roberts published their report on the first radioiodine therapy (1941) for Graves' disease, at that time still predominantly using the 130iodine isotope with a half-life of 12.4 hours. At the same time, Joseph Gilbert Hamilton (1907-1957) and John Hundale Lawrence (1904-1991) performed the first therapy with 131iodine, the isotope still used today. Radioiodine therapy is subject to special legal regulations in many countries, and in Germany may only be performed on an inpatient basis. There are approximately 120 treatment centers in Germany (as of 2014), performing approximately 50,000 treatments per year. In Germany, the minimum length of stay is 48 hours. Discharge depends on the residual activity remaining in the body. In 1999, the limit for residual activity was raised. The dose rate may not exceed 3.5 μSv per hour at a distance of 2 meters from the patient, which means that a radiation exposure of 1 mSv may not be exceeded within one year at a distance of 2 meters. This corresponds to a residual activity of about 250 MBq. Similar regulations exist in Austria.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.